Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Oak Family Advisors LLC

Oak Family Advisors LLC grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 21.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 80,644 shares of the medical equipment provider's stock after purchasing an additional 14,209 shares during the period. Zimmer Biomet comprises approximately 3.1% of Oak Family Advisors LLC's holdings, making the stock its 5th biggest holding. Oak Family Advisors LLC's holdings in Zimmer Biomet were worth $9,127,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Stonebridge Financial Group LLC bought a new stake in Zimmer Biomet during the fourth quarter worth about $25,000. Menard Financial Group LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter worth approximately $30,000. Accredited Wealth Management LLC bought a new stake in Zimmer Biomet during the 4th quarter worth approximately $36,000. Kentucky Trust Co bought a new stake in Zimmer Biomet during the 4th quarter worth approximately $39,000. Finally, OFI Invest Asset Management acquired a new stake in Zimmer Biomet during the 4th quarter valued at $40,000. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Trading Down 2.2%

Shares of NYSE:ZBH traded down $2.03 during mid-day trading on Friday, reaching $91.23. The stock had a trading volume of 1,370,283 shares, compared to its average volume of 1,790,451. The firm has a 50 day simple moving average of $96.48 and a two-hundred day simple moving average of $103.56. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.22 and a twelve month high of $116.71. The firm has a market cap of $18.05 billion, a PE ratio of 20.50, a price-to-earnings-growth ratio of 1.95 and a beta of 0.72. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm's revenue was up 1.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.94 EPS. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.05%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.24%.

Analyst Ratings Changes

Several analysts have recently commented on the company. The Goldman Sachs Group decreased their target price on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a report on Tuesday, May 6th. BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Royal Bank of Canada dropped their target price on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Truist Financial set a $101.00 target price on shares of Zimmer Biomet in a research report on Tuesday, May 6th. Finally, Robert W. Baird lowered their price target on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Zimmer Biomet presently has a consensus rating of "Hold" and an average target price of $111.53.

Insider Transactions at Zimmer Biomet

In related news, insider Sang Yi sold 1,000 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the sale, the insider now owns 20,424 shares of the company's stock, valued at approximately $1,940,280. This trade represents a 4.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.39% of the stock is owned by insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.